Alnylam Pharmaceuticals: A Tale Of  Continuous Product Growth and Expansion into New Markets!

Despite the potential subpopulation differences, the management team at Alnylam Pharmaceuticals Inc. reaffirmed their belief that their Alnylam P5x25 strategy will ultimately deliver significant financial results. The first quarter of 2024 witnessed substantial progress for Alnylam. The robust product revenue growth for the four wholly-owned medicines culminated in $365 million in revenue, which is a 32% increase year-over-year compared to the same period in 2023. Much of this growth can be credited to the stable performance of the TTR franchise, which saw 29% year-over-year growth.